Global General Technologies Inc.

Global General Technologies Inc. operates one main subsidiary: AB (Wuhan) Biotech Co. Ltd.

AB (Wuhan) Biotech Co. Ltd.

AB (Wuhan) Biotech Co. Ltd. is committed to developing, commercializing and popularizing advanced In Vitro Diagnostic (IVD) kits/devices to improve human health.

The company's primary business is to design, develop, patent and market home-applicable diagnostic test kits and portable diagnostic devices related to cardiovascular diseases and infectious diseases, specifically for the early detection of acute myocardial infarction (AMI), AIDS and others.

AB (Wuhan) Biotech Co. Ltd.'s principal objective is to become a leading supplier in molecular diagnosis and home-applicable end-user IVD markets. In the long run, the company wants to be the leader in the development and production of high quality, cutting-edge diagnostic products for human diseases.

AB (Wuhan) Biotech Co. Ltd. also makes a difference in developing unique, rapid, simple, cost-effective and high-performance diagnostic tests for use in resource-limited settings in both the developing and developed worlds. These tests will be particularly applicable to clinical settings where rapid and immediate test results are crucial.